Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 253

The DOI matches its Crossref record; 85 of the 85 references it cites were found in a registry or an index.

Type-Specific Cell Line Models for Type-Specific Ovarian Cancer Research

Open access
Anglesio, Michael S., Wiegand, Kimberly C., Melnyk, Nataliya, Chow, Christine, Salamanca, Clara, Prentice, Leah M., Senz, Janine, Yang, Winnie, Spillman, Monique A., Cochrane, Dawn R., Shumansky, Karey, Shah, Sohrab P., Kalloger, Steve E., Huntsman, David G. · 2013 · PLoS ONE

Abstract

BACKGROUND: OVARIAN CARCINOMAS CONSIST OF AT LEAST FIVE DISTINCT DISEASES: high-grade serous, low-grade serous, clear cell, endometrioid, and mucinous. Biomarker and molecular characterization may represent a more biologically relevant basis for grouping and treating this family of tumors, rather than site of origin. Molecular characteristics have become the new standard for clinical pathology, however development of tailored type-specific therapies is hampered by a failure of basic research to recognize that model systems used to study these diseases must also be stratified. Unrelated model systems do offer value for study of biochemical processes but specific cellular context needs to be applied to assess relevant therapeutic strategies. METHODS: We have focused on the identification of clear cell carcinoma cell line models. A panel of 32 "ovarian cancer" cell lines has been classified into histotypes using a combination of mutation profiles, IHC mutation-surrogates, and a validated immunohistochemical model. All cell lines were identity verified using STR analysis. RESULTS: Many described ovarian clear cell lines have characteristic mutations (including ARID1A and PIK3CA) and an overall molecular/immuno-profile typical of primary tumors. Mutations in TP53 were present in the majority of high-grade serous cell lines. Advanced genomic analysis of bona-fide clear cell carcinoma cell lines also support copy number changes in typical biomarkers such at MET and HNF1B and a lack of any recurrent expressed re-arrangements. CONCLUSIONS: As with primary ovarian tumors, mutation status of cancer genes like ARID1A and TP53 and a general immuno-profile serve well for establishing histotype of ovarian cancer cell We describe specific biomarkers and molecular features to re-classify generic "ovarian carcinoma" cell lines into type specific categories. Our data supports the use of prototype clear cell lines, such as TOV21G and JHOC-5, and questions the use of SKOV3 and A2780 as models of high-grade serous carcinoma.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0072162

Cites

85 of 85 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 8

  1. JW Carlson, 2010, Serous tubal intraepithelial carcinoma: diagnostic reproducibility and its implications, Int J Gynecol Pathol, 29, 310, 10.1097/PGP.0b013e3181c713a8 · doi:10.1097/pgp.0b013e3181c713a8
  2. AR Laury, 2011, Fallopian tube correlates of ovarian serous borderline tumors, Am J Surg Pathol, 35, 1759, 10.1097/PAS.0b013e318233b0f7 · doi:10.1097/pas.0b013e318233b0f7
  3. Schiavone MB, Herzog TJ, Lewin SN, Deutsch I, Sun X, <etal>et al</etal>.. (2011) Natural history and outcome of mucinous carcinoma of the ovary. Am J Obstet Gynecol 205: 480 e481–488. · doi:10.1016/j.ajog.2011.06.049
  4. Kommoss S, Gilks CB, Kommoss F, Anglesio MS, Chow C, <etal>et al</etal>.. (2013) Accelerating type-specific ovarian carcinoma research: Calculator for Ovarian Subtype Prediction (COSP) is a reliable high-throughput tool for case review. Histopathology (accepted June 2, 2013). · DOI
  5. M Kobel, 2011, Biomarker expression in pelvic high-grade serous carcinoma: comparison of ovarian and omental sites, Int J Gynecol Pathol, 30, 366, 10.1097/PGP.0b013e31820d20ba · DOI
  6. Farley JH, Brady WE, Birrer MJ, Lankes H, Coleman R, <etal>et al</etal>.. (2012) A phase II trial of selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum. AACR Annual Meeting 2012, Chicogo, IL, USA. · doi:10.1158/1538-7445.am2012-ct-05
  7. E Hernandez, 1984, Interobserver variability in the interpretation of epithelial ovarian cancer, Gynecol Oncol, 17, 117, 10.1016/0090-8258(84)90065-9 · doi:10.1016/0090-8258(84)90065-9
  8. A Sakamoto, 1994, Observer disagreement in histological classification of ovarian tumors in Japan, Gynecol Oncol, 54, 54, 10.1006/gyno.1994.1165 · doi:10.1006/gyno.1994.1165

Cited by

See all 253

Metadata

Authors
Anglesio, M. S., Wiegand, K. C., Melnyk, N., Chow, C., Salamanca, C., Prentice, L. M., Senz, J., Yang, W., Spillman, M. A., Cochrane, D. R., Shumansky, K., Shah, S. P., Kalloger, S. E., & Huntsman, D. G.
Venue
PLoS ONE
Published
2013-09-04
Volume
8
Issue
9
Pages
e72162
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2025669441
Cited by
253
References
85
FWCI
23.70
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.